

## SARS-CoV S1 Protein (HEK293, Fc-Avi)

Cat. No.:	HY-P78348
Synonyms:	S1 protein; Spike protein S1; Spike,S1 protein; S glycoprotein Subunit1
Species:	Virus
Source:	HEK293
Accession:	P59594 (S14-R667)
Gene ID:	1489668
Molecular Weight:	120-140 kDa

### PROPERTIES

Biological Activity	Immobilized Human ACE2, His Tag at 2µg/ml (100µl/well) on the plate. Dose response curve for SARS Spike S1, hFc Tag with the EC <sub>50</sub> of 1.7µg/ml determined by ELISA.
Appearance	Lyophilized powder.
Formulation	Lyophilized from a 0.22 µm filtered solution of PBS, pH 7.4. Normally 5% trehalose is added as protectant before lyophilization.
Endotoxin Level	<1 EU/µg, determined by LAL method.
Reconstitution	It is not recommended to reconstitute to a concentration less than 100 µg/mL in ddH <sub>2</sub> O.
Storage & Stability	Stored at -20°C for 2 years. After reconstitution, it is stable at 4°C for 1 week or -20°C for longer (with carrier protein). It is recommended to freeze aliquots at -20°C or -80°C for extended storage.
Shipping	Room temperature in continental US; may vary elsewhere.

### DESCRIPTION

Background	The SARS-CoV S protein is implicated in down-regulating host tetherin (BST2) through lysosomal degradation, thus counteracting its antiviral activity. In the context of infection, the S protein attaches the virion to the cell membrane by interacting with host receptors, initiating the viral entry process. The binding to human ACE2 and CLEC4M/DC-SIGNR receptors, coupled with the subsequent internalization of the virus into the endosomes of the host cell, induces conformational changes in the S glycoprotein. Additionally, proteolysis by cathepsin CTSL may unmask the fusion peptide of S2, activating membrane fusion within endosomes. These orchestrated events underscore the pivotal role of the SARS-CoV S protein in mediating viral entry and evading host antiviral defenses, shedding light on its significance in the pathogenesis of SARS-CoV infections. Further exploration is crucial to unveil the intricate molecular mechanisms underlying these processes and to identify potential targets for therapeutic interventions.
------------	--

---

**Caution: Product has not been fully validated for medical applications. For research use only.**

Tel: 609-228-6898

Fax: 609-228-5909

E-mail: [tech@MedChemExpress.com](mailto:tech@MedChemExpress.com)

Address: 1 Deer Park Dr, Suite Q, Monmouth Junction, NJ 08852, USA